

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI116250

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Paul F. Bray	02/27/2023
Robert A. Campbell	08/30/2023
Michelle Stoller	10/17/2022
RECEIVING PARTY DATA	
Company Name:	UNIVERSITY OF UTAH
Street Address:	201 president's circle
City:	salt lake city
State/Country:	UTAH
Postal Code:	84112
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17934816
CORRESPONDENCE DATA	
Fax Number:	3122220818
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	+1(312)222-0800
Email:	CHIIPDOCKET@MICHAELBEST.COM
Correspondent Name:	MICHAEL R. LANGER
Address Line 1:	444 W. LAKE STREET, SUITE 3200
Address Line 4:	CHICAGO, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	026389-9327-US02
NAME OF SUBMITTER:	Himanshu Thakur
SIGNATURE:	Himanshu Thakur
DATE SIGNED:	03/24/2024
Total Attachments: 5	
source=U-7271-026389-9327-US02-ASSIGNMENT-UU-03-24-24#page1.tif	
source=U-7271-026389-9327-US02-ASSIGNMENT-UU-03-24-24#page2.tif	
source=U-7271-026389-9327-US02-ASSIGNMENT-UU-03-24-24#page3.tif	
source=U-7271-026389-9327-US02-ASSIGNMENT-UU-03-24-24#page4.tif	

ASSIGNMENT

Pursuant to our obligation to the **UNIVERSITY OF UTAH** (hereinafter referred to as "Assignee"), having its principal place of business at:

201 President's Circle
Salt Lake City, UT 84112
USA

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

Paul F. Bray

c/o UNIVERSITY OF UTAH RESEARCH FOUNDATION,
615 Arapeen Drive, Suite #310
Salt Lake City, UT 84108
USA

Robert A. Campbell

c/o UNIVERSITY OF UTAH RESEARCH FOUNDATION,
615 Arapeen Drive, Suite #310
Salt Lake City, UT 84108
USA

Michelle Stoller

c/o bioMérieux,,
515 Colorow Rd
Salt Lake City, UT 84108
USA

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest -

(1) in and to inventions described in a patent application titled "FUNCTIONAL AND THERAPEUTIC EFFECTS OF PAR4 CLEAVAGE BY CATHEPSIN G" for which we filed United States Non-Provisional Patent Application No. 17/934,816 on September 23, 2022 (Attorney Docket No. 026389-9327-US02) (hereinafter "U.S. non-provisional patent application"), which claims priority to United States Provisional Patent Application No. 63/247,636, filed on September 23, 2021;

(2) in and to the U.S. non-provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. non-provisional patent application and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on the U.S. non-provisional patent application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent.

2/27/2023

Date

Date

Date

DocuSigned by:

Paul Bray

15E9E124E11B400...

Paul F. Bray

Robert A. Campbell

Michelle Stoller

ASSIGNMENT

Pursuant to our obligation to the **UNIVERSITY OF UTAH** (hereinafter referred to as "Assignee"), having its principal place of business at:

201 President's Circle
Salt Lake City, UT 84112
USA

and for other valuable and sufficient consideration, receipt whereof is hereby acknowledged, we:

Paul F. Bray

c/o UNIVERSITY OF UTAH RESEARCH FOUNDATION,
615 Arapeen Drive, Suite #310
Salt Lake City, UT 84108
USA

Robert A. Campbell

c/o UNIVERSITY OF UTAH RESEARCH FOUNDATION,
615 Arapeen Drive, Suite #310
Salt Lake City, UT 84108
USA

Michelle Stoller

c/o bioMérieux,,
515 Colorow Rd
Salt Lake City, UT 84108
USA

confirm our obligation to and hereby sell, assign and convey, unto Assignee, its successors and assigns, our entire right, title and interest -

(1) in and to inventions described in a patent application titled "FUNCTIONAL AND THERAPEUTIC EFFECTS OF PAR4 CLEAVAGE BY CATHEPSIN G" for which we filed United States Non-Provisional Patent Application No. 17/934,816 on September 23, 2022 (Attorney Docket No. 026389-9327-US02) (hereinafter "U.S. non-provisional patent application"), which claims priority to United States Provisional Patent Application No. 63/247,636, filed on September 23, 2021;

(2) in and to the U.S. non-provisional patent application, in and to all other patent applications (including divisional, continuation, continuation-in-part, and reissue applications) based upon said inventions, and in and to the patent or patents to be granted thereon, to the full end of the term or terms for which said patent or patents may be granted;

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. non-provisional patent application and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on the U.S. non-provisional patent application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent.


Date

8/30/2023

Date

Date

Paul F. Bray

DocuSigned by:

B2EDB9C7FDEF421...

Robert A. Campbell

Michelle Stoller

(3) in and to all patent applications on said invention now or hereafter filed in countries foreign to the United States of America, and in and to any and all patents granted on said applications to the full end of the terms for which said patents may be granted; and

(4) under the International Convention in respect to the U.S. non-provisional patent application and agree that any patent applications of any foreign countries which may be filed shall be filed in the name of our Assignee with a claim to priority based on the U.S. non-provisional patent application.

We hereby agree that we will, upon demand of Assignee, its successors or assigns, and without further consideration to us, execute any and all papers that may be necessary, or deemed by Assignee, its successors or assigns, to be necessary, to a complete fulfillment of the intent and purposes of this Assignment, it being understood that any expense incident to the execution of such papers shall be paid by Assignee, its successors and assigns, and not by us.

The Commissioner of Patents and Trademarks of the United States is hereby authorized and requested to issue said patent.

Date

Paul F. Bray

Attorney in Fact

Robert A. Campbell

Attorney in Fact